Figure 2
From: The impact of KRAS mutations on VEGF-A production and tumour vascular network
Expression and activity of VEGF-A in KRAS transfectants. A) VEGF-A mRNA levels were measured by RT-PCR in ASP13 or CYS12 cells. Data are expressed as average ± S.E. of 2-ΔCT (ASP13: 0.468 ± 0.12; CYS12: 0.253 ± 0.08; P = 0.07) B) VEGF-A protein levels were measured by ELISA in conditioned media from NIH3T3 control cells, ASP13 and CYS12 transfectants (NIH3T3: 51.8 ± 3.9 pg VEGF-A165/ml medium; ASP13: 630.69 ± 12.1 pg VEGF-A165/ml medium; CYS12: 119.14 ± 6.9 pg VEGF-A165/ml medium) ASP13 cell increase five times VEGF-A 165 protein expression than CYS12. (P < 0.05). C) Conditioned media obtained from NIH3T3 control cells, ASP13 and CYS12 transfectants was added to HUVEC cells cultured and thymidine incorporation measured. Results are average ± S.E. of 3 independent experiments. The conditioned media from ASP13 transfectants increased HUVEC proliferation.